FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040342201> ?p ?o ?g. }

• W3040342201 endingPage "A02" @default.
• W3040342201 startingPage "A02" @default.
• W3040342201 abstract "Abstract Introduction: Ovarian cancer metastasizes via the transcoelomic route and yields overwhelmingly numerous micrometastases. This clinical presentation limits the value of standard of care and contributes to patient mortality. Whereas EMT is required in the acquisition of a migratory phenotype, MET has been shown to occur on secondary sites leading to the establishment of metastasis. The nature of the ovarian cancer cells that result after MET is, however, yet to be fully characterized. Whether these secondary epithelial ovarian cancer cells (sEOC) are required to repeat EMT in order to generate additional metastatic sites is not known. The objectives of this study are twofold: to determine if full MET occurs on secondary sites, and to determine mechanisms that confer to disseminated ovarian cancer cells the ability to rapidly spread and form the characteristic micrometastatic disease. Materials and Methods: Ovarian cancer spheroids were derived from three epithelial ovarian cancer (EOC) cell lines (OVCAR3, R182, R2615). sEOC were derived from the spheroids by plating in tissue culture-treated plates. Gene signature pattern was determined by RNAseq. mRNA and protein levels were quantified by RT-qPCR and Western blot, respectively. TWIST-1 activity was measured by a luciferase reporter system. Promoter binding was determined by anti-CBX7 chromatin IP followed by PCR. CBX7 was knocked out (KO) using CRISPR-Cas9. Tumorigenic potential was quantified by measuring resulting intraperitoneal burden (g) in nude mice. Results: PCA and clustering analysis of RNA-seq data showed sEOC do not fully recapitulate the molecular signature of the primary EOC cells from which they are derived. Despite displaying an epithelial morphology, sEOC maintain a high expression of the classical mesenchymal effector, TWIST-1. TWIST-1 is, however, transcriptionally inactive in these cells as it is inhibited by the PcG protein, CBX7. KO of CBX7 in sEOC was sufficient to promote a mesenchymal morphology, significantly promote TWIST-1-induced transcription of mir-199A (p = 0.004, wt vs. CBX7KO), and induce higher protein levels of FOXC2. CBX7 precludes TWIST-1 from accessing its promoter by binding at or near the E box. Finally, KO of CBX7 was able to significantly enhance tumorigenicity and increase tumor load and metastatic potential in vivo (p=0.033, wt vs CBX7 KO). Conclusion: We demonstrate that full MET does not occur in ovarian cancer cells at secondary metastatic sites. Although sEOC display an epithelial morphology, they do not achieve the full molecular signature of the primary EOC cells from which they are derived. sEOC maintain high levels of TWIST-1 whose activity is inhibited by CBX7. This regulation allows secondary tumors to achieve an epithelial morphology while conferring the advantage to achieve a prompt reversal to a mesenchymal morphology and gain in tumorigenic potential upon perturbation of CBX7. This may explain ovarian cancer’s rapid progression and characteristic micrometastatic disease. Citation Format: Juanni Li, Ayesha B Alvero, Sudhakar Nuti, Roslyn Tedja, Cai M. Roberts, Mary Pitruzzello, Yimin Li, Qing Xiao, Sai Zhang, Yaqi Gan, Gil Mor, Gang Yin. CBX7 binds TWIST-1’s E-box to inhibit TWIST-1 function and curtail tumorigenecity and metastatic potential in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A02." @default.
• W3040342201 created "2020-07-10" @default.
• W3040342201 creator A5007804227 @default.
• W3040342201 creator A5009063631 @default.
• W3040342201 creator A5030926332 @default.
• W3040342201 creator A5032264417 @default.
• W3040342201 creator A5036392650 @default.
• W3040342201 creator A5037637302 @default.
• W3040342201 creator A5042125139 @default.
• W3040342201 creator A5057464314 @default.
• W3040342201 creator A5070139617 @default.
• W3040342201 creator A5078106091 @default.
• W3040342201 creator A5088903979 @default.
• W3040342201 creator A5090881669 @default.
• W3040342201 date "2020-07-01" @default.
• W3040342201 modified "2023-10-17" @default.
• W3040342201 title "Abstract A02: CBX7 binds TWIST-1’s E-box to inhibit TWIST-1 function and curtail tumorigenecity and metastatic potential in ovarian cancer" @default.
• W3040342201 doi "https://doi.org/10.1158/1557-3265.ovca19-a02" @default.
• W3040342201 hasPublicationYear "2020" @default.
• W3040342201 type Work @default.
• W3040342201 sameAs 3040342201 @default.
• W3040342201 citedByCount "0" @default.
• W3040342201 crossrefType "journal-article" @default.
• W3040342201 hasAuthorship W3040342201A5007804227 @default.
• W3040342201 hasAuthorship W3040342201A5009063631 @default.
• W3040342201 hasAuthorship W3040342201A5030926332 @default.
• W3040342201 hasAuthorship W3040342201A5032264417 @default.
• W3040342201 hasAuthorship W3040342201A5036392650 @default.
• W3040342201 hasAuthorship W3040342201A5037637302 @default.
• W3040342201 hasAuthorship W3040342201A5042125139 @default.
• W3040342201 hasAuthorship W3040342201A5057464314 @default.
• W3040342201 hasAuthorship W3040342201A5070139617 @default.
• W3040342201 hasAuthorship W3040342201A5078106091 @default.
• W3040342201 hasAuthorship W3040342201A5088903979 @default.
• W3040342201 hasAuthorship W3040342201A5090881669 @default.
• W3040342201 hasConcept C121608353 @default.
• W3040342201 hasConcept C2779013556 @default.
• W3040342201 hasConcept C2780427987 @default.
• W3040342201 hasConcept C502942594 @default.
• W3040342201 hasConcept C54355233 @default.
• W3040342201 hasConcept C71924100 @default.
• W3040342201 hasConcept C86803240 @default.
• W3040342201 hasConcept C96232424 @default.
• W3040342201 hasConceptScore W3040342201C121608353 @default.
• W3040342201 hasConceptScore W3040342201C2779013556 @default.
• W3040342201 hasConceptScore W3040342201C2780427987 @default.
• W3040342201 hasConceptScore W3040342201C502942594 @default.
• W3040342201 hasConceptScore W3040342201C54355233 @default.
• W3040342201 hasConceptScore W3040342201C71924100 @default.
• W3040342201 hasConceptScore W3040342201C86803240 @default.
• W3040342201 hasConceptScore W3040342201C96232424 @default.
• W3040342201 hasIssue "13_Supplement" @default.
• W3040342201 hasLocation W30403422011 @default.
• W3040342201 hasOpenAccess W3040342201 @default.
• W3040342201 hasPrimaryLocation W30403422011 @default.
• W3040342201 hasRelatedWork W1499339123 @default.
• W3040342201 hasRelatedWork W2333142390 @default.
• W3040342201 hasRelatedWork W2568845480 @default.
• W3040342201 hasRelatedWork W2972524777 @default.
• W3040342201 hasRelatedWork W3114532332 @default.
• W3040342201 hasRelatedWork W3158604434 @default.
• W3040342201 hasRelatedWork W3173207637 @default.
• W3040342201 hasRelatedWork W4304116770 @default.
• W3040342201 hasRelatedWork W4362568092 @default.
• W3040342201 hasRelatedWork W4380354235 @default.
• W3040342201 hasVolume "26" @default.
• W3040342201 isParatext "false" @default.
• W3040342201 isRetracted "false" @default.
• W3040342201 magId "3040342201" @default.
• W3040342201 workType "article" @default.